pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2019-29-5-612-619pulmo-1231Research ArticleОБЗОРЫREVIEWПерспективы применения пробиотических препаратов при острых инфекциях респираторного трактаPerspectives of treatment with probiotics in acute respiratory infectionsИвашкинВ. Т.IvashkinV. T.

Ивашкин Владимир Трофимович – доктор медицинских наук, профессор, академик  Российской академии  наук,  заведующий  кафедрой  пропедевтики внутренних болезней   лечебного   факультета,   директор   Клиники  пропедевтики внутренних   болезней,   гастроэнтерологии  и  гепатологии   им.  В.Х.Василенко.

119991,  Москва,  ул. Трубецкая, 8, стр. 2.

тел.: (499) 248-35-12

Vladimir T. Ivashkin - Doctor  of Medicine,  professor, Academician of Russian Academy of Sciences, Head of Department of Propaedeutics of Internal  Diseases, Therapeutic  Faculty,  Direcror  of V.Kh.Vasilenko Clinics of Propaedeutics of Internal  Diseases, Gastroenterology and Hepatology,  I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia.

ul. Trubetskaya 8, build. 2, Moscow, 119991.

kont07@yandex.ruЗольниковаО. Ю.Zol’nikovaO. Yu.

Зольникова Оксана Юрьевна – кандидат медицинских наук, доцент кафедры пропедевтики внутренних  болезней  лечебного факультета.

119991,  Москва,  ул. Трубецкая, 8, стр. 2.

тел.: (499) 248-35-12

Oksana Yu. Zol’nikova - Candidate  of Medicine,  Associate Professor, Department of Propaedeutics of Internal Diseases, Therapeutic  Faculty, I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia.

ul. Trubetskaya 8, build. 2, Moscow, 119991.

ks.med@mail.ruПоцхверашвилиН. Д.PotskhverashviliN. D.

Поцхверашвили Нино Димитровна – врач отделения пульмонологии Клиники пропедевтики внутренних болезней,  гастроэнтерологии и гепатологии им. В.Х.Василенко.

119991,  Москва,  ул. Трубецкая, 8, стр. 2.

тел.: (499) 248-35-12

Nino  D.  Potskhverashvili - physician,  Department of Pulmonology,   V.Kh.Vasilenko  Clinics  of Propaedeutics of Internal  Diseases,  Gastroenterology and Hepatology,  I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia.

ul. Trubetskaya 8, build. 2, Moscow, 119991.

nino.med@mail.ruКокинаН. И.KokinaN. I.

Кокина Наталия Ивановна – кандидат медицинских наук, доцент кафедры  пропедевтики внутренних  болезней  лечебного  факультета.

119991,  Москва,  ул. Трубецкая, 8, стр. 2.

тел.: (499) 248-35-12

Nataliya I. Kokina, Candidate - of Medicine,  Associate Professor, Department of Propaedeutics of Internal Diseases, Therapeutic  Faculty, I.M.Sechenov First Moscow State Medical  University (Sechenov  University),  Healthcare Ministry of Russia.

ul. Trubetskaya 8, build. 2, Moscow, 119991.

kokinanatalia@gmail.comБуевероваЕ. Л.BuyeverovaE. L.

Буеверова Елена Леонидовна – кандидат медицинских наук, ассистент кафедры пропедевтики внутренних болезней лечебного факультета.

119991,  Москва,  ул. Трубецкая, 8, стр. 2.

тел.: (499) 248-35-12

Elena L. Buyeverova - Candidate  of Medicine,  Assistant Lecturer,  Department of Propaedeutics of Internal  Diseases, Therapeutic  Faculty, I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia.

ul. Trubetskaya 8, build. 2, Moscow, 119991.

ele-bueverova@yandex.ruСедоваА. В.SedovaA. V.

Седова Алла Владимировна – кандидат медицинских наук, ассистент  кафедры  пропедевтики внутренних  болезней  лечебного факультета.

119991,  Москва,  ул. Трубецкая, 8, стр. 2.

тел.: (499) 248-35-12

Alla V. Sedova - Candidate  of Medicine,  Assistant Lecturer,  Department of Propaedeutics of Internal  Diseases, Therapeutic  Faculty, I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia.

ul. Trubetskaya 8, build. 2, Moscow, 119991.

sedovaav@yandex.ruТрухмановА. С.TrukhmanovA. S.

Трухманов Александр Сергеевич – доктор медицинских наук,  профессор кафедры  пропедевтики внутренних  болезней  лечебного  факультета.

119991,  Москва,  ул. Трубецкая, 8, стр. 2.

тел.: (499) 248-35-12

Aleksandr S. Trukhmanov - Doctor  of Medicine,  Professor, Department of Propaedeutics of Internal  Diseases, Therapeutic  Faculty, I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia.

ul. Trubetskaya 8, build. 2, Moscow, 119991.

alexander.trukhmanov@gmail.comПервый Московский государственный медицинский университет имени И.М.Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияI.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of RussiaRussian Federation201925122019295612619Copyright © Ивашкин В.Т., Зольникова О.Ю., Поцхверашвили Н.Д., Кокина Н.И., Буеверова Е.Л., Седова А.В., Трухманов А.С., 20192019Ивашкин В.Т., Зольникова О.Ю., Поцхверашвили Н.Д., Кокина Н.И., Буеверова Е.Л., Седова А.В., Трухманов А.С.Ivashkin V.T., Zol’nikova O.Y., Potskhverashvili N.D., Kokina N.I., Buyeverova E.L., Sedova A.V., Trukhmanov A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1231

Острые  вирусные  инфекции верхних  дыхательных  путей  (ВДП)  являются  одним  из самых  распространенных заболеваний в мире. Заболевание возникает  у лиц всех возрастных  групп и в некоторых случаях может иметь неблагоприятные осложнения и исходы. Одна из приоритетных задач практического здравоохранения состоит в возможности профилактики и лечения  острой респираторной вирусной инфекции и ее осложнений. В представленном обзоре рассмотрены собственные механизмы  неспецифической защиты человеческого организма  от вирусной инфекции. Обобщены  результаты исследований по изучению роли симбионтной кишечной микрофлоры в профилактике острой инфекции ВДП. На основании имеющихся литературных  данных представлены  основные  аспекты биологических свойств пробиотических бактерий,  которые,  как правило,  рассматриваются в контексте  их модулирующего  влияния на воспалительную иммунную реакцию.  Проведен  анализ имеющихся данных о снижении риска возникновения, продолжительности и выраженности симптомов  респираторной инфекции при приеме пробиотических препаратов  (ПБП) как в детском возрасте,  так и во взрослой популяции. Обсуждается  вопрос  штаммоспецифического эффекта  ПБП.  В статье рассмотрены основные  возможные  молекулярные противовирусные механизмы  ПБП, за счет которых симбионтные бактерии усиливают противовирусный ответ.

Аcute respiratory infection (ARI) is one of the most prevalent diseases worldwide. The disease occurs in any age, so its course could be associated with complications  and poor outcome.  Prevention  and treatment of ARI and complications  are important  problems in clinical practice.  Recent researches of human microbiome  composition  and functions have aroused a great interest to this field in order to prevent ARIs.

In this review, the authors discuss non-specific  mechanisms  of human  innate antiviral defense and available data about a role of symbiontic intestinal microf lora for ARI prevention. Typically, main biological properties of probiotic bacteria are considered in the context of modulating effects on the inf lammatory immune response. Published data demonstrated reduction in the risk, severity and duration of ARI under the treatment with probiotic agents both in the children and in adults. The strain-specific effect and potential molecular antiviral mechanisms of probiotics enhancing the antiviral response of symbiontic bacteria are also discussed in the review.

респираторная инфекцияпробиотические препаратыиммуномодуляциямикробиом человекамикробиота кишечникаrespiratory tract infectionsprobioticsimmunomodulationhuman microbiomeintestinal microbiotaReferencesAllander T., Tammi M.T., Eriksson M. et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. USA. 2005; 102 (36): 12891–12896. DOI: 10.1073/pnas.0504666102.Allander T., Tammi M.T., Eriksson M. et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. USA. 2005; 102 (36): 12891–12896. DOI: 10.1073/pnas.0504666102.Rossi G.A., Colin A.A. Infantile respiratory syncytial virus and human rhinovirus infections: respective role in inception and persistence of wheezing. Eur. Respir. J. 2015; 45 (3): 774–789. DOI: 10.1183/09031936.00062714.Rossi G.A., Colin A.A. Infantile respiratory syncytial virus and human rhinovirus infections: respective role in inception and persistence of wheezing. Eur. Respir. J. 2015; 45 (3): 774–789. DOI: 10.1183/09031936.00062714.Openshaw P.J., Tregoning J.S. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev. 2005; 18 (3): 541–555. DOI: 10.1128/CMR.18.3.541-555.2005.Openshaw P.J., Tregoning J.S. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev. 2005; 18 (3): 541–555. DOI: 10.1128/CMR.18.3.541-555.2005.Gauguet S., D'Ortona S., Ahnger-Pier K. et al. Intestinal microbiota of mice inf luences resistance to Staphylococcus aureus pneumonia. Infect. Immun. 2015; 83 (10): 4003–4014. DOI: 10.1128/IAI.00037-15.Gauguet S., D'Ortona S., Ahnger-Pier K. et al. Intestinal microbiota of mice inf luences resistance to Staphylococcus aureus pneumonia. Infect. Immun. 2015; 83 (10): 4003–4014. DOI: 10.1128/IAI.00037-15.Ichiohe T., Pang I.K., Kumamoto Y. et al. Microbiota regulates immune defense against respiratory tract inf luenza A virus infection. Proc. Natl. Acad. Sci. USA. 2011; 108 (13): 5354–5359. DOI: 10.1073/pnas.1019378108.Ichiohe T., Pang I.K., Kumamoto Y. et al. Microbiota regulates immune defense against respiratory tract inf luenza A virus infection. Proc. Natl. Acad. Sci. USA. 2011; 108 (13): 5354–5359. DOI: 10.1073/pnas.1019378108.Salva S., Alvarez S. The role of microbiota and immunobiotics in granulopoiesis of immunocompromised hosts. Front. Immunol. 2017; 8: 507. DOI: 10.3389/fimmu.2017.00507.Salva S., Alvarez S. The role of microbiota and immunobiotics in granulopoiesis of immunocompromised hosts. Front. Immunol. 2017; 8: 507. DOI: 10.3389/fimmu.2017.00507.Lopez P., Gonzalez-Rodrıguez I., Gueimonde M. et al. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS ONE. 2011; 6 (9): e24776. DOI: 10.1371/journal.pone.0024776.Lopez P., Gonzalez-Rodrıguez I., Gueimonde M. et al. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS ONE. 2011; 6 (9): e24776. DOI: 10.1371/journal.pone.0024776.Izumo T., Maekawa T., Ida M. et al. Effect of intranasal administration of Lactobacillus pentosus S-PT84 on inf luenza virus infection in mice. Int. Immunopharmacol. 2010; 10 (9): 1101–1106. DOI: 10.1016/j.intimp.2010.06.012.Izumo T., Maekawa T., Ida M. et al. Effect of intranasal administration of Lactobacillus pentosus S-PT84 on inf luenza virus infection in mice. Int. Immunopharmacol. 2010; 10 (9): 1101–1106. DOI: 10.1016/j.intimp.2010.06.012.Kobayashi N., Saito T., Uematsu T. et al. Oral administration of heat-killed Lactobacillus pentosus strain b240 augments protection against inf luenza virus infection in mice. Int. Immunopharmacol. 2011; 11 (2): 199–203. DOI: 10.1016/j.intimp.2010.11.019.Kobayashi N., Saito T., Uematsu T. et al. Oral administration of heat-killed Lactobacillus pentosus strain b240 augments protection against inf luenza virus infection in mice. Int. Immunopharmacol. 2011; 11 (2): 199–203. DOI: 10.1016/j.intimp.2010.11.019.Hori T., Kiyoshima J., Shida K., Yasui H. Effect of intranasal administration of Lactobacillus casei Shirota on inf luenza virus infection of upper respiratory tract in mice. Clin. Diagn. Lab. Immunol. 2001; 8 (3): 593–597. DOI: 10.1128/CDLI.8.3.593-597.2001.Hori T., Kiyoshima J., Shida K., Yasui H. Effect of intranasal administration of Lactobacillus casei Shirota on inf luenza virus infection of upper respiratory tract in mice. Clin. Diagn. Lab. Immunol. 2001; 8 (3): 593–597. DOI: 10.1128/CDLI.8.3.593-597.2001.Yasui H., Kiyoshima J., Hori T. Reduction of inf luenza virus titer and protection against inf luenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin. Diagn. Lab. Immunol. 2004; 11 (4): 675–679. DOI: 10.1128/CDLI.11.4.675-679.2004.Yasui H., Kiyoshima J., Hori T. Reduction of inf luenza virus titer and protection against inf luenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin. Diagn. Lab. Immunol. 2004; 11 (4): 675–679. DOI: 10.1128/CDLI.11.4.675-679.2004.Pang I.K., Iwasaki A. Control of antiviral immunity by pattern recognition and the microbiome. Immunol. Rev. 2012; 245 (1): 209–226. DOI: 10.1111/j.1600-065X.2011.01073.x.Pang I.K., Iwasaki A. Control of antiviral immunity by pattern recognition and the microbiome. Immunol. Rev. 2012; 245 (1): 209–226. DOI: 10.1111/j.1600-065X.2011.01073.x.Villena J., Suzuki R., Fujie H. et al. Immunobiotic Lactobacillus jensenii modulates the Toll-like receptor 4-induced inf lammatory response via negative regulation in porcine antigen-presenting cells. Clin. Vaccine Immunol. 2012; 19 (7): 1038–1053. DOI: 10.1128/CVI.00199-12.Villena J., Suzuki R., Fujie H. et al. Immunobiotic Lactobacillus jensenii modulates the Toll-like receptor 4-induced inf lammatory response via negative regulation in porcine antigen-presenting cells. Clin. Vaccine Immunol. 2012; 19 (7): 1038–1053. DOI: 10.1128/CVI.00199-12.Nagai T., Makino S., Ikegami S. et al. Effects of oral administration of yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 and its exopolysaccharides against inf luenza virus infection in mice. Int. Immunopharmacol. 2011; 11 (12): 2246–2250. DOI: 10.1016/j.intimp.2011.09.012.Nagai T., Makino S., Ikegami S. et al. Effects of oral administration of yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 and its exopolysaccharides against inf luenza virus infection in mice. Int. Immunopharmacol. 2011; 11 (12): 2246–2250. DOI: 10.1016/j.intimp.2011.09.012.Kawase M., He F., Kubota A. et al. Oral administration of lactobacilli from human intestinal tract protects mice against inf luenza virus infection. Lett. Appl. Microbiol. 2010; 51 (1): 6–10. DOI: 10.1111/j.1472-765X.2010.02849.x.Kawase M., He F., Kubota A. et al. Oral administration of lactobacilli from human intestinal tract protects mice against inf luenza virus infection. Lett. Appl. Microbiol. 2010; 51 (1): 6–10. DOI: 10.1111/j.1472-765X.2010.02849.x.Harata G., He F., Hiruta N. et al. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 inf luenza virus infection by regulating respiratory immune responses. Lett. Appl. Microbiol. 2010; 50 (6): 597–602. DOI:10.1111/j.1472-765X.2010.02844.x.Harata G., He F., Hiruta N. et al. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 inf luenza virus infection by regulating respiratory immune responses. Lett. Appl. Microbiol. 2010; 50 (6): 597–602. DOI:10.1111/j.1472-765X.2010.02844.x.Kawase M., He F., Kubota A. et al. Heat-killed Lactobacillus gasseri TMC0356 protects mice against inf luenza virus infection by stimulating gut and respiratory immune responses. FEMS Immunol. Med. Microbiol. 2012; 64 (2): 280–288. DOI: 10.1111/j.1574-695X.2011.00903.x.Kawase M., He F., Kubota A. et al. Heat-killed Lactobacillus gasseri TMC0356 protects mice against inf luenza virus infection by stimulating gut and respiratory immune responses. FEMS Immunol. Med. Microbiol. 2012; 64 (2): 280–288. DOI: 10.1111/j.1574-695X.2011.00903.x.Maruo T., Gotoh Y., Nishimura H. et al. Oral administration of milk fermented with Lactococcus lactis subsp. cremoris FC protects mice against inf luenza virus infection. Lett. Appl. Microbiol. 2012; 55 (2): 135–140. DOI: 10.1111/j.1472-765X.2012.03270.x.Maruo T., Gotoh Y., Nishimura H. et al. Oral administration of milk fermented with Lactococcus lactis subsp. cremoris FC protects mice against inf luenza virus infection. Lett. Appl. Microbiol. 2012; 55 (2): 135–140. DOI: 10.1111/j.1472-765X.2012.03270.x.Goto H., Sagitani A., Ashida N. et al. Anti-inf luenza virus effects of both live and non-live Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity. Br. J. Nutr. 2013; 110 (10): 1810–1818. DOI: 10.1017/S0007114513001104.Goto H., Sagitani A., Ashida N. et al. Anti-inf luenza virus effects of both live and non-live Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity. Br. J. Nutr. 2013; 110 (10): 1810–1818. DOI: 10.1017/S0007114513001104.Yasui H., Kiyoshima J., Hori T., Shida K. Protection against inf luenza virus infection of mice fed Bif idobacterium breve YIT4064. Clin. Diagn. Lab. Immunol. 1999; 6 (2): 186–192.Yasui H., Kiyoshima J., Hori T., Shida K. Protection against inf luenza virus infection of mice fed Bif idobacterium breve YIT4064. Clin. Diagn. Lab. Immunol. 1999; 6 (2): 186–192.Gabryszewski S.J., Bachar O., Dyer K.D. et al. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J. Immunol. 2011; 186 (2): 1151–1161. DOI: 10.4049/jimmunol.1001751.Gabryszewski S.J., Bachar O., Dyer K.D. et al. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J. Immunol. 2011; 186 (2): 1151–1161. DOI: 10.4049/jimmunol.1001751.Tomosada Y., Chiba E., Zelaya H. et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol. 2013; 14: 40. DOI: 10.1186/1471-2172-14-40.Tomosada Y., Chiba E., Zelaya H. et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol. 2013; 14: 40. DOI: 10.1186/1471-2172-14-40.Gill H.S., Rutherfurd K.J., Cross M.L., Gopal P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 2001; 74 (6): 833–839. DOI: 10.1093/ajcn/74.6.833.Gill H.S., Rutherfurd K.J., Cross M.L., Gopal P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 2001; 74 (6): 833–839. DOI: 10.1093/ajcn/74.6.833.Di Cerbo A., Palmieri B., Aponte M. et al. Mechanisms and therapeutic effectiveness of lactobacilli. J. Clin. Pathol. 2016; 69 (3): 187–203. DOI: 10.1136/jclinpath-2015-202976.Di Cerbo A., Palmieri B., Aponte M. et al. Mechanisms and therapeutic effectiveness of lactobacilli. J. Clin. Pathol. 2016; 69 (3): 187–203. DOI: 10.1136/jclinpath-2015-202976.Hatakka K., Savilahti E., Pönkä A. et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. Br. Med. J. 2001; 322 (7298): 1327. DOI: 10.1136/bmj.322.7298.1327.Hatakka K., Savilahti E., Pönkä A. et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. Br. Med. J. 2001; 322 (7298): 1327. DOI: 10.1136/bmj.322.7298.1327.Hojsak I., Snovak N., Abdovic S. et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin. Nutr. 2010; 29 (3): 312–316. DOI: 10.1016/j.clnu.2009.09.008.Hojsak I., Snovak N., Abdovic S. et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin. Nutr. 2010; 29 (3): 312–316. DOI: 10.1016/j.clnu.2009.09.008.Kumpu M., Kekkonen R.A., Kautiainen H. et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur. J. Clin. Nutr. 2012; 66 (9): 1020–1023. DOI: 10.1038/ejcn.2012.62.Kumpu M., Kekkonen R.A., Kautiainen H. et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur. J. Clin. Nutr. 2012; 66 (9): 1020–1023. DOI: 10.1038/ejcn.2012.62.Luoto R., Ruuskanen O., Waris M. et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2014; 133 (2): 405–413. DOI: 10.1016/j.jaci.2013.08.020.Luoto R., Ruuskanen O., Waris M. et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2014; 133 (2): 405–413. DOI: 10.1016/j.jaci.2013.08.020.Kukkonen K., Savilahti E., Haahtela T. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008; 122 (1): 8–12. DOI: 10.1542/peds.2007-1192.Kukkonen K., Savilahti E., Haahtela T. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008; 122 (1): 8–12. DOI: 10.1542/peds.2007-1192.Rautava S., Salminen S., Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br. J. Nutr. 2009; 101 (11): 1722–1726. DOI: 10.1017/S0007114508116282.Rautava S., Salminen S., Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br. J. Nutr. 2009; 101 (11): 1722–1726. DOI: 10.1017/S0007114508116282.Agustina R., Kok F.J., van de Rest O. et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012; 129 (5): e1155–1164. DOI: 10.1542/peds.2011-1379.Agustina R., Kok F.J., van de Rest O. et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012; 129 (5): e1155–1164. DOI: 10.1542/peds.2011-1379.Turchet P., Laurenzano M., Auboiron S., Antoine J.M. Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in freeliving elderly subjects: a randomised, controlled pilot study. J. Nutr. Health Aging. 2003; 7 (2): 75–77.Turchet P., Laurenzano M., Auboiron S., Antoine J.M. Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in freeliving elderly subjects: a randomised, controlled pilot study. J. Nutr. Health Aging. 2003; 7 (2): 75–77.Guillemard E., Tondu F., Lacoin F., Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 2010; 103 (1): 58–68. DOI: 10.1017/S0007114509991395.Guillemard E., Tondu F., Lacoin F., Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 2010; 103 (1): 58–68. DOI: 10.1017/S0007114509991395.Cobo Sanz J.M., Mateos J.A., Muñoz Conejo A. [Effect of Lactobacillus casei on the incidence of infectious conditions in children]. Nutr. Hosp. 2006; 21 (4): 547–551 (in Spanish).Cobo Sanz J.M., Mateos J.A., Muñoz Conejo A. [Effect of Lactobacillus casei on the incidence of infectious conditions in children]. Nutr. Hosp. 2006; 21 (4): 547–551 (in Spanish).Lin J.S., Chiu Y.H., Lin N.T. et al. Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study. Vaccine. 2009; 27 (7): 1073–1079. DOI: 10.1016/j.vaccine.2008.11.114.Lin J.S., Chiu Y.H., Lin N.T. et al. Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study. Vaccine. 2009; 27 (7): 1073–1079. DOI: 10.1016/j.vaccine.2008.11.114.Nocerino R., Paparo L., Terrin G. et al. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: a randomized controlled trial. Clin Nutr. 2017; 36 (1): 118–125. DOI: 10.1016/j.clnu.2015.12.004.Nocerino R., Paparo L., Terrin G. et al. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: a randomized controlled trial. Clin Nutr. 2017; 36 (1): 118–125. DOI: 10.1016/j.clnu.2015.12.004.Maldonado J., Cañabate F., Sempere L. et al. Human milk probiotic Lactobacillus fermentum CECT57I6 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J. Pediatr. Gastroenterol. Nutr. 2012; 54 (1): 55–61. DOI: 10.1097/MPG.0b013e3182333f18.Maldonado J., Cañabate F., Sempere L. et al. Human milk probiotic Lactobacillus fermentum CECT57I6 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J. Pediatr. Gastroenterol. Nutr. 2012; 54 (1): 55–61. DOI: 10.1097/MPG.0b013e3182333f18.Hojsak I., Močić Pavić A., Kos T. et al. Bifidobacterium animalis subsp. lactis in prevention of common infections in healthy children attending day care centers – randomized, double blind, placebo-controlled study. Clin. Nutr. 2016; 35 (3): 587–591. DOI: 10.1016/j.clnu.2015.05.004.Hojsak I., Močić Pavić A., Kos T. et al. Bifidobacterium animalis subsp. lactis in prevention of common infections in healthy children attending day care centers – randomized, double blind, placebo-controlled study. Clin. Nutr. 2016; 35 (3): 587–591. DOI: 10.1016/j.clnu.2015.05.004.Garaiova I., Muchová J., Nagyová Z. et al. Probiotics and vitamin C for the prevention of respiratory tract infections in children attending preschool: a randomised controlled pilot study. Eur. J. Clin. Nutr. 2015; 69 (3): 373–379. DOI: 10.1038/ejcn.2014.174.Garaiova I., Muchová J., Nagyová Z. et al. Probiotics and vitamin C for the prevention of respiratory tract infections in children attending preschool: a randomised controlled pilot study. Eur. J. Clin. Nutr. 2015; 69 (3): 373–379. DOI: 10.1038/ejcn.2014.174.de Vrese M., Winkler P., Rautenberg P. et al. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin. Nutr. 2005; 24 (4): 481–491. DOI: 10.1016/j.clnu.2005.02.006.de Vrese M., Winkler P., Rautenberg P. et al. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin. Nutr. 2005; 24 (4): 481–491. DOI: 10.1016/j.clnu.2005.02.006.Guillemard E., Tondu F., Lacoin F., Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 2010; 103 (1): 58–68. DOI: 10.1017/S0007114509991395.Guillemard E., Tondu F., Lacoin F., Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 2010; 103 (1): 58–68. DOI: 10.1017/S0007114509991395.Makino S., Ikegami S., Kume A. et al. Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. Br. J. Nutr. 2010; 104 (7): 998–1006. DOI: 10.1017/S000711451000173X.Makino S., Ikegami S., Kume A. et al. Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. Br. J. Nutr. 2010; 104 (7): 998–1006. DOI: 10.1017/S000711451000173X.Namba K., Hatano M., Yaeshima T. et al. Effects of Bifidobacterium longum BB536 administration on inf luenza infection, inf luenza vaccine antibody titer, and cell-mediated immunity in the elderly. Biosci. Biotechnol. Biochem. 2010; 74 (5): 939–945. DOI: 10.1271/bbb.90749.Namba K., Hatano M., Yaeshima T. et al. Effects of Bifidobacterium longum BB536 administration on inf luenza infection, inf luenza vaccine antibody titer, and cell-mediated immunity in the elderly. Biosci. Biotechnol. Biochem. 2010; 74 (5): 939–945. DOI: 10.1271/bbb.90749.Hamilton-Miller J.M. Probiotics and prebiotics in the elderly. Postgrad. Med. J. 2004; 80 (946): 447–451. DOI: 10.1136/pgmj.2003.015339.Hamilton-Miller J.M. Probiotics and prebiotics in the elderly. Postgrad. Med. J. 2004; 80 (946): 447–451. DOI: 10.1136/pgmj.2003.015339.Davidson L.E., Fiorino A.M., Snydman D.R., Hibberd P.L. Lactobacillus GG as an immune adjuvant for live-attenuated inf luenza vaccine in healthy adults: a randomized doubleblind placebo-controlled trial. Eur. J. Clin. Nutr. 2011; 65 (4): 501–507. DOI: 10.1038/ejcn.2010.289.Davidson L.E., Fiorino A.M., Snydman D.R., Hibberd P.L. Lactobacillus GG as an immune adjuvant for live-attenuated inf luenza vaccine in healthy adults: a randomized doubleblind placebo-controlled trial. Eur. J. Clin. Nutr. 2011; 65 (4): 501–507. DOI: 10.1038/ejcn.2010.289.Akatsu H., Arakawa K., Yamamoto T. et al. Lactobacilli in jelly enhances the effect of inf luenza vaccination in Elderly Individuals. J. Am. Geriatr. Soc. 2013; 61 (10): 1828–1830. DOI: 10.1111/jgs.12474.Akatsu H., Arakawa K., Yamamoto T. et al. Lactobacilli in jelly enhances the effect of inf luenza vaccination in Elderly Individuals. J. Am. Geriatr. Soc. 2013; 61 (10): 1828–1830. DOI: 10.1111/jgs.12474.Rizzardini G., Eskesen D., Calder P.C. et al. Evaluation of the immune benef its of two probiotic strains Bif idobacterium animalis ssp. lactis, BB-12 and Lactobacillus paracasei ssp. paracasei, L. casei 431 in an inf luenza vaccination model: a randomized, double-blind, placebo controlled study. Brit. J. Nutr. 2012; 107 (6): 876–884. DOI: 10.1017/S000711451100420X.Rizzardini G., Eskesen D., Calder P.C. et al. Evaluation of the immune benef its of two probiotic strains Bif idobacterium animalis ssp. lactis, BB-12 and Lactobacillus paracasei ssp. paracasei, L. casei 431 in an inf luenza vaccination model: a randomized, double-blind, placebo controlled study. Brit. J. Nutr. 2012; 107 (6): 876–884. DOI: 10.1017/S000711451100420X.Hao Q., Dong B.R., Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database System. Rev. 2015; (2): CD006895. DOI: 10.1002/14651858.CD006895.pub3.Hao Q., Dong B.R., Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database System. Rev. 2015; (2): CD006895. DOI: 10.1002/14651858.CD006895.pub3.Wang Y., Li X., Ge Т. et al. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95 (31): e4509. DOI: 10.1097/MD.0000000000004509.Wang Y., Li X., Ge Т. et al. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95 (31): e4509. DOI: 10.1097/MD.0000000000004509.Fitzgerald K.A. NLR-containing inf lammasomes: Central mediators of host defense and inf lammation. Eur. J. Immunol. 2010; 40 (3): 595–598. DOI: 10.1002/eji.201040331.Fitzgerald K.A. NLR-containing inf lammasomes: Central mediators of host defense and inf lammation. Eur. J. Immunol. 2010; 40 (3): 595–598. DOI: 10.1002/eji.201040331.Coulombe F., Fiola S., Akira S. et al. Muramyl dipeptide induces NOD2-dependent Ly6Chigh monocyte recruitment to the lungs and protects against inf luenza virus infection. PLoS One. 2012; 7 (5): e36734. DOI: 10.1371/journal.pone.0036734.Coulombe F., Fiola S., Akira S. et al. Muramyl dipeptide induces NOD2-dependent Ly6Chigh monocyte recruitment to the lungs and protects against inf luenza virus infection. PLoS One. 2012; 7 (5): e36734. DOI: 10.1371/journal.pone.0036734.Lehtoranta L., Pitkäranta A., Korpela R. Probiotics in respiratory virus infections. Eur. J. Clin. Microbiol. Infect. Dis. 2014; 33 (8): 1289–1302. DOI: 10.1007/s10096-014-2086-y.Lehtoranta L., Pitkäranta A., Korpela R. Probiotics in respiratory virus infections. Eur. J. Clin. Microbiol. Infect. Dis. 2014; 33 (8): 1289–1302. DOI: 10.1007/s10096-014-2086-y.Kim T.H., Lee H.K. Differential roles of lung dendritic cell subsets against respiratory virus infection. Immune Netw. 2014; 14 (3): 128–137. DOI: 10.4110/in.2014.14.3.128.Kim T.H., Lee H.K. Differential roles of lung dendritic cell subsets against respiratory virus infection. Immune Netw. 2014; 14 (3): 128–137. DOI: 10.4110/in.2014.14.3.128.Manzanares W., Lemieux M., Langlois P.L., Wischmeyer P.L. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit. Care. 2016; 20: 262. DOI: 10.1186/s13054-016-1434-y.Manzanares W., Lemieux M., Langlois P.L., Wischmeyer P.L. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit. Care. 2016; 20: 262. DOI: 10.1186/s13054-016-1434-y.

The authors declare that there are no conflicts of interest present.